| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/12/2012 | WO2012003784A1 Pyrazine derivatives,process for manufacture and use thereof |
| 01/12/2012 | WO2012003563A1 Antineoplastic pharmaceutical compositions containing substituted nitroaromatic compounds |
| 01/12/2012 | WO2012003562A1 Antineoplastic pharmaceutical compositions containing substituted nitroimidazoles |
| 01/12/2012 | WO2012003544A1 Protein kinase inhibitors and methods of treatment |
| 01/12/2012 | WO2011145629A3 ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION |
| 01/12/2012 | WO2011133584A3 Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
| 01/12/2012 | WO2011133010A3 Molecular iodine composition for human use for the prevention and treatment of prostatic pathologies |
| 01/12/2012 | WO2011129427A9 Diagnostic agent and therapeutic agent for cancer |
| 01/12/2012 | WO2011123678A3 Substituted benzo-pyrido-triazolo-diazepine compounds |
| 01/12/2012 | WO2011112900A3 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| 01/12/2012 | WO2011109411A9 Sandalwood oil and its uses |
| 01/12/2012 | WO2011109353A3 Immunosuppressant extracts derived from millettia laurentii or pseudotsuga pinaceae |
| 01/12/2012 | WO2011107867A3 Compound and composition and their use in the treatment of diseases related to copper retention |
| 01/12/2012 | WO2011106577A3 Method for treating brain cancer |
| 01/12/2012 | WO2011103413A3 Taxane pro-emulsion formulations and methods making and using the same |
| 01/12/2012 | WO2011100685A3 Methods of generating hyper inos expressing cells and uses thereof |
| 01/12/2012 | WO2011094708A3 Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders |
| 01/12/2012 | WO2011068934A4 Vaccine against neoplastic or cancerous lesions caused by human papillomavirus (hpv), procedures, uses and methods |
| 01/12/2012 | WO2011047173A3 Pharmaceutical compositions for oral administration |
| 01/12/2012 | WO2010135524A8 Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
| 01/12/2012 | US20120010601 Orthopedic cement and use of same in radiation therapy |
| 01/12/2012 | US20120010499 Use of nanoparticles for the treatment of cancer |
| 01/12/2012 | US20120010287 N, n -dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| 01/12/2012 | US20120010282 Tautomycetin and Tautomycetin Analog Biosynthesis |
| 01/12/2012 | US20120010278 Use of Artemisinin for Treating Tumors Induced by Oncogenic Viruses and for Treating Viral Infections |
| 01/12/2012 | US20120010267 RNAi MODULATION OF MLL-AF4 AND USES THEREOF |
| 01/12/2012 | US20120010266 Tbc1d7 as tumor marker and therapeutic target for cancer |
| 01/12/2012 | US20120010257 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/12/2012 | US20120010248 Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof |
| 01/12/2012 | US20120010247 Bicyclic compound |
| 01/12/2012 | US20120010245 Transdermal pharmaceutical compositions comprising a serm |
| 01/12/2012 | US20120010241 Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof |
| 01/12/2012 | US20120010240 CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR |
| 01/12/2012 | US20120010235 N-substituted pyrrolidines |
| 01/12/2012 | US20120010230 Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| 01/12/2012 | US20120010229 Therapeutic regimens for hedgehog-associated cancers |
| 01/12/2012 | US20120010213 Oral controlled release dosage forms for water soluble drugs |
| 01/12/2012 | US20120010204 Phthalazinone Derivatives |
| 01/12/2012 | US20120010203 Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| 01/12/2012 | US20120010200 Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same |
| 01/12/2012 | US20120010197 Protein kinase inhibitors |
| 01/12/2012 | US20120010191 Pyridone and aza-pyridone compounds and methods of use |
| 01/12/2012 | US20120010181 Compounds for the treatment of inflammatory disorders |
| 01/12/2012 | US20120010177 MicroRNA Modulators and Method for Identifying And Using The Same |
| 01/12/2012 | US20120010174 Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin |
| 01/12/2012 | US20120010172 Novel urea and thiourea derivatives |
| 01/12/2012 | US20120010165 Potentiator of radiation therapy |
| 01/12/2012 | US20120010156 Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| 01/12/2012 | US20120010155 Gntiii expression in plants |
| 01/12/2012 | US20120010154 Cytotoxic Conjugates Having Neuropeptide Y Receptor Binding Compound |
| 01/12/2012 | US20120010153 Novel tumor-targeting compounds |
| 01/12/2012 | US20120010152 Targeting of Podoplanin with Lectin for Use in the Prevention and Treatment of Cancer |
| 01/12/2012 | US20120010151 Use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer |
| 01/12/2012 | US20120010149 Peptide combination |
| 01/12/2012 | US20120010137 Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer |
| 01/12/2012 | US20120010126 Recombinant surfactant protein d compositions and methods of use thereof |
| 01/12/2012 | US20120010124 Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell |
| 01/12/2012 | US20120009648 DNA polymerase lambda and uses thereof |
| 01/12/2012 | US20120009282 Use of the combination of phy906 and a tyrosine kinase inhibitor as a cancer treatment regimen |
| 01/12/2012 | US20120009277 Method for selection of novel anti-cancer herbs using cheminformatic tools |
| 01/12/2012 | US20120009268 Modified Virus Vectors and Methods of Making and Using the Same |
| 01/12/2012 | US20120009265 Drug carrier |
| 01/12/2012 | US20120009252 Liposomal formulations of anthracycline agents and cytidine analogs |
| 01/12/2012 | US20120009251 Cholestanol derivative for combined use |
| 01/12/2012 | US20120009247 Phospholipid drug analogs |
| 01/12/2012 | US20120009246 Phospholipid-analogous compounds |
| 01/12/2012 | US20120009243 Liposomes for drug delivery and methods for preparation thereof |
| 01/12/2012 | US20120009240 Films for Delivery of a Therapeutic Agent |
| 01/12/2012 | US20120009221 Transfection of blood cells with mrna for immune stimulation and gene therapy |
| 01/12/2012 | US20120009211 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins |
| 01/12/2012 | US20120009206 Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| 01/12/2012 | US20120009204 Treatment of Metastatic Breast Cancer |
| 01/12/2012 | US20120009203 Depletion of cancer stem cells |
| 01/12/2012 | US20120009201 Renal cell carcinoma biomarkers |
| 01/12/2012 | US20120009200 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment |
| 01/12/2012 | US20120009199 Antibody formulations |
| 01/12/2012 | US20120009197 Anti-Human Equilibrative Nucleoside Transporter 1 (hENT1) Antibodies and Methods of Use Thereof |
| 01/12/2012 | US20120009196 Monoclonal antibodies against hepatitis c virus core protein |
| 01/12/2012 | US20120009195 Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| 01/12/2012 | US20120009194 Antibodies to endoplasmin and their use |
| 01/12/2012 | US20120009193 Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same |
| 01/12/2012 | US20120009188 Optimized fc variants |
| 01/12/2012 | US20120009186 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 01/12/2012 | US20120009181 Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof |
| 01/12/2012 | US20120009173 Cytotoxic ribonuclease variants |
| 01/12/2012 | US20120009162 T cell receptor and nucleic acid encoding the receptor |
| 01/12/2012 | US20120009153 Compositions for bacterial mediated gene silencing and methods of using the same |
| 01/12/2012 | US20120009151 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof |
| 01/12/2012 | US20120009145 Biodegradable Cross-Linked Cationic Multi-block Copolymers for Gene Delivery and Methods of Making Thereof |
| 01/12/2012 | US20120009143 Treating non-hematopoietic cancer with interleukin 6 |
| 01/12/2012 | US20120009141 Functionalized pyrrolidines and use thereof as iap inhibitors |
| 01/12/2012 | US20120009140 Compostition and therapeutic anti-tumour vaccine |
| 01/12/2012 | US20120009123 Albumin binding peptide-mediated disease targeting |
| 01/12/2012 | US20120009122 Gastrin releasing peptide compounds |
| 01/12/2012 | DE112009001815T5 Herstellungsverfahren für bioabbaubare Mikropartikel, welche Arzneistoffe enthalten Contain manufacturing method for biodegradable microparticles which drugs |
| 01/12/2012 | CA2805065A1 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof |
| 01/12/2012 | CA2804918A1 N-hydroxyformamide derivative and medicament containing same |
| 01/12/2012 | CA2804915A1 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof |
| 01/12/2012 | CA2804648A1 Protein kinase inhibitors and methods of treatment |
| 01/12/2012 | CA2804599A1 Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |